Conclusion
In the U.S., maternal morbidity and mortality is increasing, and there
is a need to target populations at higher risks. Taken together, our
findings suggest that tackling adverse perinatal outcomes in AYA cancer
survivors involves mitigating pre- and intra-pregnancy comorbidities
this population experiences as a result of cancer and related treatment.
Our findings are clinically significant, because they inform counseling,
screening, and medical management to prevent and manage both
comorbidities as well as the adverse perinatal outcomes of preterm birth
and severe maternal morbidity. Next, detailing which specific cancer
treatments, beyond broad categories of chemotherapy, radiation, and
surgery, are related to which maternal comorbidity is needed to
prioritize research and clinical screening and surveillance. Future
studies that leverage claims data to measure more detailed exposures may
be feasible and valid.48-50